semaglutide compound being discontinued Compounded (GLP-1) FDA Ends Compounded GLP-1s: What

In 2019, the American Diabetes Association/European Association for the Study of Diabetes published an updated consensus report on the treatment of hyperglycemia recommending GLP-1 receptor agonist inhibitors as agents of choice in patients with established cardiovascular disease and especially in those with specific indicators of high cardiovascular risk [5]

The company does have a broad pipeline (over 100 programs in various stages), which provides diversification, but statistically, only a fraction will become blockbusters

& Boesze-Battaglia, K

This includes allowing pharmacists to administer more routine medicines, such as injectable buprenorphine, enoxaparin ( Clexane ), denosumab ( Prolia ), risperidone, insulin or vitamin B12, to improve the management of complex health conditions

Am J Clin Dermatol 22(1):5565

doi: 10.1016/j.autrev.2007.11.007 8 MizokamiTWu LiAEl-KaissiSWallJR